

Moderator:



***Tracey Ely, Vice President, Oncology Portfolio Strategy, Johnson & Johnson
Innovative Medicine***

Tracy is the Vice President of Oncology Portfolio Strategy & Execution at Johnson & Johnson. She is committed to helping her team deliver solutions to health system customers and the patients they serve. She is inspired by the mission to reimagine care so patients can redefine living, and works every day to improve education, understanding, and access to J&J's strong and advancing portfolio of therapies for solid tumor and hematologic malignancies. She believes that in the face of a dynamic ecosystem, we must remain agile and adaptable so that we can help patients live longer and better through life's big and small milestones.

Panelists:



Richard R. Barakat, MD, MBA, Physician-in-Chief & Executive Director, Northwell Cancer Institute, Edward & Carole Miller Distinguished Chair in Cancer, Senior Vice President, Cancer Services, Northwell Health

Richard Barakat is an internationally recognized surgeon and clinical investigator who was Chief of the Gynecology Service at Memorial Sloan Kettering from 2001 to 2013 and held the Ronald O. Perelman Chair in Gynecologic Surgery. Dr. Barakat was the lead investigator on several influential clinical trials at MSK, including a study to compare the benefits of laparoscopic versus standard surgery for patients with endometrial cancer and was the lead investigator on an NIH funded national study evaluating symptomatic lower-extremity lymphedema in women undergoing lymphadenectomy for cervical, uterine and vulvar cancer. Dr. Barakat is author or co-author of more than 340 peer-reviewed articles and numerous textbook chapters and was the lead editor of *Principles and Practice of Gynecologic Oncology*, one of the leading texts in the field.

In addition, he served as a member and examiner for the American Board of Obstetrics and Gynecology and for five years served as a director of the Division of Gynecologic Oncology.

He was President of the Society of Gynecologic Oncology from 2013 to 2014 and past President of the International Gynecologic Cancer Society (2014-2016). After obtaining his MBA from Columbia Business school in 2014, he served as Director of the MSK regional care network and Cancer Alliance until 2017.

In 2018 Dr. Barakat joined Northwell Health to lead all cancer services and research and serve as professor of Obstetrics and Gynecology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. In his current role he oversees nine cancer centers under the Northwell Cancer Institute, which care for over 20,000 new patients annually, making Northwell the largest provider of cancer services in New York. Dr. Barakat works closely with the leadership of Cold Spring Harbor Laboratory which has a permanent partnership with Northwell, as the Cancer Institute works towards achieving NCI designation as a Consortium.



Sinan Sanvar, MHA, Vice President of Enterprise Growth and Business Development, Memorial Sloan Kettering Cancer Center

Sinan Sanvar is the Vice President of Enterprise Growth and Business Development at Memorial Sloan Kettering Cancer Center (MSKCC) leading enterprise wide strategic and business development initiatives. He has 25 years of healthcare experience having worked in various strategy, finance, operations, and business development roles at large academic medical centers. Prior to joining MSKCC, he served as the Executive Director of Enterprise Strategy at Stanford Medicine and Stanford Health Care responsible for strategic planning, business development and strategic initiatives for the clinical and academic enterprise. He previously led partnership and business development portfolio as the Executive Director of Business Development at MD Anderson Cancer Center responsible for the growth and expansion of MD Anderson Cancer Center in regional, national, and global markets. Prior to joining MD Anderson Cancer Center, he led Johns Hopkins Medicine's business development initiatives and served as the Chief Operating Officer of joint ventures in Abu Dhabi and Singapore where he was responsible for the growth and day-to-day management

of Johns Hopkins Medicine's assets. He began his career at the Cleveland Clinic in Ohio where he completed his administrative fellowship and served as the Finance Director. He earned his Master's in Health Administration degree from the Medical College of Virginia and Bachelor's degree in Economics from Bilkent University.



Kai Tsao, MD, MS, Associate Professor of Medicine, Medical Director, Ruttenberg Treatment Center, Medical Director, Medical Oncology Prostate Cancer Program, Tisch Cancer Institute, Mount Sinai Hospital, Mount Sinai Health System

Kai Tsao MD MS is the Medical Director of the Ruttenberg Treatment Center at the Mount Sinai Hospital, and the Medical Director of the Medical Oncology Prostate Cancer Program at the Tisch Cancer Institute. He is an Associate Professor of Hematology, Oncology, and Medicine at the Icahn School of Medicine at Mount Sinai. He was the Chief Fellow during his Hematology and Oncology fellowship training, and is the recipient of the annual Mount Sinai Hospital Fellow Physician of the year award in 2012. As a physician-clinical investigator specialized in genitourinary cancers, he has authored over 70 peer reviewed paper to date, and is the recipient of several research awards from the American Society of Clinical Oncology (ASCO). His research focus is on the development of biomarkers and novel therapies for Prostate and Kidney cancers. He is the principal investigator of numerous ongoing phase I-III clinical trials. He is currently the reviewer and editor of several urology and oncology peer reviewed journals, and is regularly invited to lecture globally. He is the recipient of Tisch Cancer Institute's Solid Tumor faculty teacher of the year in 2023.

With focus in improving healthcare delivery, he completed Lean Six Sigma training at Johns Hopkins University in 2017, and completed the Masters of Healthcare Delivery at the Icahn School of Medicine in 2019. He is a disciple of patient-centered care, using a combination of data-driven analytics and LEAN principles in improving cancer care. He has led several international oncology collaborations on behalf of Mount Sinai International, in countries including Vietnam, China, Guyana, and India. In this role since 2017, he has led teams of multi-disciplinary experts in collaboration with international partners to develop healthcare delivery strategy, improve cancer center and hospital infrastructure, implement quality driven process improvement, and prepare for Joint Commission International accreditation.



***Jonathan M. Gerber, MD, Chief Clinical Officer, Perlmutter Cancer Center, NYU
Langone Health***

Dr. Gerber received his B.A. (Phi Beta Kappa) in Biology from Johns Hopkins University and his M.D. (Alpha Omega Alpha) from the Johns Hopkins School of Medicine, where he also completed his Internal Medicine residency and Hematology fellowship. Upon completion of his training, he served on the faculty of the Johns Hopkins School of Medicine and Johns Hopkins Hospital for 5 years, in the Division of Hematology.

In 2013, Dr. Gerber joined the newly created Levine Cancer Institute of the Carolinas HealthCare System in Charlotte, North Carolina to found and lead its Leukemia Program, as well as to help start the Blood and Marrow Transplantation (BMT) Program, performing the first allogeneic BMT in an adult in the city of Charlotte in March of 2014. In 2018, he was then recruited to be the Chief of Hematology & Oncology; the Eleanor Eustis Farrington Chair in Cancer Research; and the Medical Director of the Cancer Service Line at UMass Memorial Health and the University of Massachusetts Chan Medical School, where he was subsequently promoted to serve as the Director of the Cancer Center. On July 1, 2024, Dr.

Gerber joined NYU Langone Health as the Chief Clinical Officer of the Laura and Isaac Perlmutter Cancer Center.

Dr. Gerber's clinical interests include leukemia and related diseases, as well as BMT and cellular therapy. He is a translational laboratory researcher and an early phase clinical trial investigator. His research focuses on the identification and targeting of the stem cells at the root of leukemia and similar diseases, with the goal of personalizing therapy and developing better treatments that are more effective and less toxic. He has received numerous awards & grants for his research; co-authored over 50 peer-reviewed articles in prominent publications; and presented at national & international meetings, as well as serving as a reviewer for the National Institutes of Health and top journals in the field. He is also a member of the editorial board and the associate editor for hematology content for HemOnc Today. His leukemia research has resulted in three U.S. patents and has been translated into clinical trials.

During the COVID pandemic, Dr. Gerber pivoted to launch a convalescent plasma program, treating the first patient in Massachusetts with this therapy. He was also a member of the team that received a 2023 Top 10 Clinical Research Achievement award from the Clinical Research Forum for their work on the treatment of COVID-19 with convalescent plasma, which was published in The New England Journal of Medicine. More recently, he served as a co-principal investigator, in collaboration with Rheumatology, to treat one of the first patients in the U.S. with chimeric antigen receptor (CAR) T cell therapy for systemic lupus erythematosus, with highly promising results. He remains involved in the development of CAR T cell therapies for other autoimmune diseases and cancers.

Dr. Gerber is an active member of several professional societies, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO).

Currently, he is a member of the ASH Subcommittee on Reimbursement and the Vice Chair

of the ASH Subcommittee on Precision Medicine, as well as a member of the ASH Continuing Certification Working Group. He previously served on the ASH Committee on Practice, the ASCO Cancer Research Committee, and the ASCO Education Committee. Dr. Gerber has also served on the boards of the Charlotte and the New England chapters of the Leukemia & Lymphoma Society. In addition, he was a member of the Massachusetts Department of Public Health's Diagnosis & Treatment Working Group for the 2024-2029 State Cancer Plan.